| scholarly article | Q13442814 |
| P2093 | author name string | Prakash G Chandak | |
| Prasad G Jamkhande | |||
| Priti S Tidke | |||
| Sonal R Barde | |||
| Ram S Sakhare | |||
| Shashikant C Dhawale | |||
| P2860 | cites work | The response-to-retention hypothesis of early atherogenesis | Q24629974 |
| Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption | Q28266499 | ||
| Cholesterol-metabolizing cytochromes P450 | Q28293552 | ||
| The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 | ||
| Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. | Q30385604 | ||
| High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study | Q30450312 | ||
| Response to injury and atherogenesis | Q33494262 | ||
| Atherosclerosis: from lesion formation to plaque activation and endothelial dysfunction | Q34067817 | ||
| Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role? | Q34208034 | ||
| Effects of menopause on intraindividual changes in serum lipids, blood pressure, and body weight--the Chin-Shan Community Cardiovascular Cohort study | Q43913015 | ||
| Management of risk factors for accelerated atherosclerosis | Q46723666 | ||
| Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis | Q47726405 | ||
| Monitoring of atherosclerosis. | Q51997179 | ||
| Adventitial dysfunction: an evolutionary model for understanding atherosclerosis. | Q52981355 | ||
| Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study | Q57417382 | ||
| P-selectin regulates platelet-activating factor synthesis and phagocytosis by monocytes | Q71705027 | ||
| The pathogenesis of atherosclerosis | Q73567705 | ||
| An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits | Q77449866 | ||
| Coronary and cerebrovascular atherosclerosis: two aspects of the same disease or two different pathologies? | Q80577786 | ||
| Hypothyroidism is not associated with increased carotid atherosclerosis when cardiovascular risk factors are accounted for in hyperlipidemic patients | Q81689766 | ||
| Effects of nasal immunization of multi-target preventive vaccines on atherosclerosis | Q83112913 | ||
| [Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?] | Q83377551 | ||
| Lifestyle and physiological risk factor profiles six weeks after an acute cardiac event: are patients achieving recommended targets for secondary prevention? | Q83724305 | ||
| Nitric oxide and atherosclerosis | Q34211736 | ||
| Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation | Q34218574 | ||
| Molecular genetics and gene expression in atherosclerosis. | Q34386072 | ||
| Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking | Q34503152 | ||
| Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression | Q34734065 | ||
| Nongenomic actions of thyroid hormone on the heart | Q34775527 | ||
| The macrophage foam cell as a target for therapeutic intervention | Q34986351 | ||
| Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis | Q35027751 | ||
| Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment | Q35029623 | ||
| Lack of acyl-CoA:diacylglycerol acyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice. | Q35571228 | ||
| Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches | Q35708128 | ||
| Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects | Q35967794 | ||
| Atherosclerotic disease and risk factor modification in Saudi Arabia: a call to action | Q36027227 | ||
| Hypertension and atherosclerosis: clinical implications from the ALLHAT Trial | Q36052971 | ||
| HDL-C and the diabetic patient: target for therapeutic intervention? | Q36161634 | ||
| Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease | Q36386686 | ||
| Leptin and atherosclerosis | Q36437593 | ||
| Nitric oxide and atherosclerosis: an update | Q36473426 | ||
| Scavenger receptors in atherosclerosis: beyond lipid uptake | Q36489900 | ||
| Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions | Q36705451 | ||
| The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation | Q36964107 | ||
| Endoglin in angiogenesis and vascular diseases | Q37088038 | ||
| Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study | Q37308160 | ||
| AMPK: an emerging drug target for diabetes and the metabolic syndrome | Q37471010 | ||
| Hyperglycemia and arterial stiffness: the Atherosclerosis Risk in the Communities study | Q37607175 | ||
| Thyroid hormone and atherosclerosis | Q37609631 | ||
| Phospholipase A2s: developing drug targets for atherosclerosis | Q37723854 | ||
| Lipoprotein-associated phospholipase A2: a new therapeutic target. | Q37729873 | ||
| Perivascular adipose tissue as a cause of atherosclerosis. | Q37774439 | ||
| The role of endoglin in atherosclerosis. | Q37998302 | ||
| The biological role of inflammation in atherosclerosis | Q38044110 | ||
| Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation | Q40631077 | ||
| DGAT2 is a new diacylglycerol acyltransferase gene family: purification, cloning, and expression in insect cells of two polypeptides from Mortierella ramanniana with diacylglycerol acyltransferase activity | Q40789063 | ||
| A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors | Q40813036 | ||
| Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan--a unique experience | Q41081978 | ||
| Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters | Q41827579 | ||
| Role for Porphyromonas gingivalis in the progression of atherosclerosis. | Q43405464 | ||
| P433 | issue | 3 | |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 179-190 | |
| P577 | publication date | 2013-11-05 | |
| P1433 | published in | Saudi Pharmaceutical Journal | Q15763912 |
| P1476 | title | Therapeutic approaches to drug targets in atherosclerosis | |
| P478 | volume | 22 |
| Q34338139 | Adiponectin abates atherosclerosis by reducing oxidative stress |
| Q38533468 | Animal models to evaluate anti-atherosclerotic drugs |
| Q36388450 | Blue-Green Algae Inhibit the Development of Atherosclerotic Lesions in Apolipoprotein E Knockout Mice. |
| Q35626888 | Dihydroaustrasulfone Alcohol (WA-25) Impedes Macrophage Foam Cell Formation by Regulating the Transforming Growth Factor-β1 Pathway. |
| Q90640923 | Ethyl acetate extract of sappanwood alleviates experimental atherosclerosis in rats through changes in FGF21 and SREBP-2 expression |
| Q36830291 | Exercise capacity and cardiac hemodynamic response in female ApoE/LDLR(-/-) mice: a paradox of preserved V'O2max and exercise capacity despite coronary atherosclerosis. |
| Q36586338 | Micellar and structural stability of nanoscale amphiphilic polymers: Implications for anti-atherosclerotic bioactivity |
| Q35685116 | Structural and ultrastructural evaluation of the aortic wall after transplantation of bone marrow-derived cells (BMCs) in a model for atherosclerosis. |
| Q38878978 | The Characteristics and Roles of Advanced Oxidation Protein Products in Atherosclerosis |
| Q38782616 | The Chemical Composition of Achillea wilhelmsii C. Koch and Its Desirable Effects on Hyperglycemia, Inflammatory Mediators and Hypercholesterolemia as Risk Factors for Cardiometabolic Disease. |
| Q86792646 | The antiatherogenic effect of bixin in hypercholesterolemic rabbits is associated to the improvement of lipid profile and to its antioxidant and anti-inflammatory effects |
| Q97530968 | The cholesterol-lowering effect of unripe Rubus coreanus is associated with decreased oxidized LDL and apolipoprotein B levels in subjects with borderline-high cholesterol levels: a randomized controlled trial |
| Q35283429 | The utility of iron chelators in the management of inflammatory disorders. |
| Q35869727 | Yindanxinnaotong, a Chinese compound medicine, synergistically attenuates atherosclerosis progress |
Search more.